Digitisation | September 02, 2022
Infosys completes acquisition of BASE life science
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Biopharma and CROs to benefit from simplified access to global research sites
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Subscribe To Our Newsletter & Stay Updated
